BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 11051618)

  • 21. In vitro activity of six beta-lactam antibiotics against non-beta-lactamase producing and producing enterobacteria and antibiotic resistance transfer.
    Scioli C; Esposito S; Martinelli R
    Boll Ist Sieroter Milan; 1984 Sep; 63(4):338-47. PubMed ID: 6335045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
    Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
    J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance to extended-spectrum beta-lactams by the emergence of SHV-12 and the loss of OmpK35 in Klebsiella pneumoniae and Escherichia coli in Malaysia.
    Palasubramaniam S; Muniandy S; Navaratnam P
    J Microbiol Immunol Infect; 2009 Apr; 42(2):129-33. PubMed ID: 19597644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Beta-lactam resistance in aquatic Enterobacter cloacae strains using phenotypic and genotypic criteria].
    Lazăr V; Cernat R; Balotescu C; Cotar A; Coipan E; Cojocaru C
    Bacteriol Virusol Parazitol Epidemiol; 2002; 47(3-4):185-91. PubMed ID: 15085610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.
    Jones RN; Sader HS; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 May; 52(1):71-4. PubMed ID: 15878447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
    Calbo E; Romaní V; Xercavins M; Gómez L; Vidal CG; Quintana S; Vila J; Garau J
    J Antimicrob Chemother; 2006 Apr; 57(4):780-3. PubMed ID: 16492721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prevalence of extended-spectrum beta-lactamase producing Escherichia coli in pediatric patients in China].
    Wang L; Yang YH; Lu Q; Wang Y; Chen Y; Deng L; Deng QL; Zhang H; Wang CQ; Liu L; Xu XW; Shen XZ
    Zhonghua Yi Xue Za Zhi; 2008 May; 88(20):1372-5. PubMed ID: 18953872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. beta-Lactam resistance and beta-lactamases in bacteria of animal origin.
    Li XZ; Mehrotra M; Ghimire S; Adewoye L
    Vet Microbiol; 2007 Apr; 121(3-4):197-214. PubMed ID: 17306475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The antimicrobial activity of mecillinam, nitrofurantoin, temocillin and fosfomycin and comparative analysis of resistance patterns in a nationwide collection of ESBL-producing Escherichia coli in Norway 2010-2011.
    Zykov IN; Sundsfjord A; Småbrekke L; Samuelsen Ø
    Infect Dis (Lond); 2016 Feb; 48(2):99-107. PubMed ID: 26414659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CTX-M-15, OXA-30 and TEM-1-producing Escherichia coli in two Portuguese regions.
    Mendonça N; Louro D; Castro AP; Diogo J; Caniça M
    J Antimicrob Chemother; 2006 May; 57(5):1014-6. PubMed ID: 16531434
    [No Abstract]   [Full Text] [Related]  

  • 31. Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase.
    Kang CI; Pai H; Kim SH; Kim HB; Kim EC; Oh MD; Choe KW
    J Antimicrob Chemother; 2004 Dec; 54(6):1130-3. PubMed ID: 15486080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of the beta-lactam resistance phenotypes of Escherichia coli. An 8-year survey conducted in Greece.
    Neonakis IK; Baritaki S; Georgiladakis A; Spandidos DA
    Roum Arch Microbiol Immunol; 2008; 67(1-2):10-3. PubMed ID: 19284160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of ertapenem and other antimicrobials against ESBL-producing enterobacteria isolated from urine in patients from Madrid.
    Tamayo J; Orden B; Cacho J; Cuadros J; Gomez-Garces JL; Alos JI
    Rev Esp Quimioter; 2007 Sep; 20(3):334-8. PubMed ID: 18080031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are beta-lactams related to higher morbidity and mortality in urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli?
    You JH; Kei HW; Lau WC; Wong KY; Marasinghe T; Lee N; Ip M
    J Hosp Infect; 2008 Feb; 68(2):181-3. PubMed ID: 18194826
    [No Abstract]   [Full Text] [Related]  

  • 35. Patterns of resistance to beta-lactams and characterization of beta-lactamases in Escherichia coli isolates from children in Tunisia.
    Réjiba S; Kechrid A
    J Chemother; 2007 Aug; 19(4):382-7. PubMed ID: 17855181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
    Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
    Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phenotypic confirmation of extended-spectrum B-lactamases (ESBL) in clinical isolates of Escherichia coli and Klebsiella pneumoniae at the San Juan Veterans Affairs Medical Center.
    Del Carmen Rodríguez M; Vera DE; Ramírez-Ronda CH; Saavedra S
    P R Health Sci J; 2004 Sep; 23(3):207-15. PubMed ID: 15631176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases.
    Shah AA; Hasan F; Ahmed S; Hameed A
    Res Microbiol; 2004; 155(6):409-21. PubMed ID: 15249058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prevalence of ESBL-producing E. coli and Klebsiella strains in the Copenhagen area of Denmark.
    Kjerulf A; Hansen DS; Sandvang D; Hansen F; Frimodt-Møller N
    APMIS; 2008 Feb; 116(2):118-24. PubMed ID: 18321362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A combination of mecillinam and amoxicillin/clavulanate can restore susceptibility of high-level TEM-1-producing Escherichia coli to mecillinam.
    Birgy A; Delecourt M; Geslain G; Desselas E; Caseris M; Magnan M; Mariani-Kurkdjian P; Bidet P; Bonacorsi S
    J Antimicrob Chemother; 2017 Jul; 72(7):1911-1914. PubMed ID: 28369441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.